未登录

J

Jian Shi

Central South University

H指数:38

被引数:4,622

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Heat stress activates the coagulation cascade through Z-DNA-binding protein 1-dependent necroptosis

热应激通过Z-DNA结合蛋白1依赖性坏死性凋亡激活凝血级联反应

IF23.1

2026-04-011

PRE

Effects of Voriconazole on the Safety; Pharmacokinetics and Pharmacodynamics of Ciprofol (HSK3486); a Novel Intravenous Anaesthetic; in Healthy Participants: A Prospective; Randomized; Crossover Clinical Trial

伏立康唑对安全性、西普罗酚（HSK3486）药代动力学和药效学的影响：一项在健康受试者中进行的西普罗酚（HSK3486）的新型静脉麻醉剂的前瞻性、随机、交叉临床试验

drug design; development and therapy

IF0

2026-01-080

OAAI

RETRACTION: Oroxylin A inhibits carcinogen-induced skin tumorigenesis through inhibition of inflammation by regulating SHCBP1 in mice

撤稿：Oroxylin A通过调节SHCBP1抑制炎症，从而抑制致癌物诱导的小鼠皮肤肿瘤发生

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2025-06-010

PRE

Stress hyperglycemia in acute pancreatitis: From mechanisms to prognostic implications

IF5.1

2025-03-010

PRE

KAT6A inhibitor screening cascade to facilitate novel drug discovery

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-010

PRE

Genome-Wide Association Study for the Genetic Determinants of Thiopurine Methyltransferase Protein Expression in Human Livers and Racial Differences

PHARMACEUTICAL RESEARCH

IF4.3

2023-07-102

PRE

Identification of regulatory variants of carboxylesterase 1 (CES1): A proof-of-concept study for the application of the Allele-Specific Protein Expression (ASPE) assay in identifying cis-acting regulatory genetic polymorphisms

IF3.9

2022-12-071

OAAI

Pharmacokinetics, Pharmacodynamics Drug Transport Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2022-09-012

OAAI

Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-11-302

OA

Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection

IF5.5

2021-10-1113

OAAI

Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-05-268

OAAI

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-03-046

OAAI

FRACPRED-2D-PRM: A Fraction Prediction Algorithm-Assisted 2D Liquid Chromatography-Based Parallel Reaction Monitoring-Mass Spectrometry Approach for Measuring Low-Abundance Proteins in Human Plasma

IF3.9

2020-11-034

OAAI

Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice

BIOCHEMICAL PHARMACOLOGY

IF5.6

2020-10-0124

OAAI

Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2020-05-0135

PREAI

Targeted proteomics analysis revealed the imbalanced allele-specific protein expression of carboxylesterase1 in human livers

IF4.2

2020-04-191

PRE

The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2020-04-0162

PREAI

Oroxylin A inhibits carcinogen-induced skin tumorigenesis through inhibition of inflammation by regulating SHCBP1 in mice

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2020-03-0116

PREAI

Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2020-02-0179

PREAI

Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver

MOLECULAR PHARMACOLOGY

IF3

2019-12-019

OAAI